MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
AVIR — Atea Pharmaceuticals, Inc. Common Stock
NasdaqAtea Pharmaceuticals, Inc. Common Stock
$5.13
+0.03(+0.59%)
- O
- 5.16
- H
- 5.22
- L
- 5.05
- V
- 253.16K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About AVIR
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateOct 30, 2020
Employees55
Stock ExchangeNasdaq
Ticker SymbolAVIR
Websitehttps://www.ateapharma.com
Key Financial Statistics
| Market Cap | $414.66M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $2.81 - $6.45 |
| 52-Week Avg Volume | 402.5K |
| VWAP | $5.13 |
| Transactions | 3,695 |
| Total Recorded Bars | 1,487 days |